<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endothelin, a potent vasoconstrictor, has been found to increase in the cerebrospinal fluid and serum of patients following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) and to play a major role in the development of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to investigate the role of endothelin-A <z:chebi fb="68" ids="48706">antagonist</z:chebi> BQ-610 in the experimentally performed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following SAH </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty New Zealand rabbits were divided into three groups (each n = 10): group A, control group; Group B, SAH group; Group C, treatment (endothelin <z:chebi fb="68" ids="48706">antagonist</z:chebi> BQ-610 treated) group </plain></SENT>
<SENT sid="3" pm="."><plain>In the study, the rabbits developed vasospasm after injection of intracisternal autolog blood into the cisterna magna </plain></SENT>
<SENT sid="4" pm="."><plain>After <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> development, in group C, endothelin <z:chebi fb="68" ids="48706">antagonist</z:chebi> BQ-610 was injected intracisternally </plain></SENT>
<SENT sid="5" pm="."><plain>Morphometrically, basilar artery lumen was constricted 25% and 62% compared to the control group (group A) in the endothelin treated group (group C) and the endothelin untreated group (group B), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Histopathological findings of the basilar artery wall confirmed the therapeutic effect of endothelin <z:chebi fb="68" ids="48706">antagonist</z:chebi> in vasospasm development </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="51452">Endothelin-A receptor antagonist</z:chebi> BQ-610 has a therapeutic effect in the <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following experimentally performed <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> when used intracisternally </plain></SENT>
</text></document>